Preliminary results of the ongoing phase 1/2 PLATFORM study evaluating the safety and efficacy of the anti-CD19 CAR T-cell product lisocabtagene maraleucel (liso-cel) in combination with durvalumab in patients with r/r DLBCL demonstrated that the combination has an acceptable safety profile, and the best ORR in a small number of patients was 91% with 64% of patients achieving a CR [56]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.